Li, B, et al. Fructose-1,6-Bisphosphatase Opposes Renal Carcinoma Progression. Nature, 2014.
Metabolon results led to:
• Identification of a new target node for pan-efficacy in clear cell renal carcinoma (ccRCC)
• Identification of a pan-ccRCC biomarker
Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer. Although (VHL) mutations occur in over 90% of ccRCC tumors, deletion of VHL in the mouse does not produce a consistent effect, suggesting that additional mechanisms are involved. To determine these mechanisms, investigators used a systems approach including metabolomics to profile primary ccRCC tumors. The results determined that the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) is uniformly depleted in over six hundred ccRCC tumors and associated with poor prognosis. Metabolomic data also pointed to a clear rationale for why - Warburg characteristics and accompanying pentose phosphate pathway flux. The identification of this single metabolic feature across all ccRCCs is another reminder that metabolomics is a key tool for cancer “omics” since it can often cut through the genomic and tumor heterogeneity to reveal common themes that can offer new targets or biomarkers.